Inducible Co-Stimulator ICOS Expression Correlates with Immune Cell Infiltration and Can Predict Prognosis in Lung Adenocarcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30. doi:10.3322/caac.21387
   PubMed Web of Science ®Google Scholar
• Shi J, Hua X, Zhu B, et al. Somatic genomics and clinical features of lung adenocarcinoma: a retrospective study. PLoS Med. 2016;13:e1002162. doi:10.1371/journal.pmed.1002162
   PubMed Web of Science ®Google Scholar
• Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–289. doi:10.3322/caac.21349
   PubMed Web of Science ®Google Scholar
• Politi K, Herbst RS. Lung cancer in the era of precision medicine. Clin Cancer Res. 2015;21:2213–2220. doi:10.1158/1078-0432.CCR-14-2748
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115‐132.
   Web of Science ®Google Scholar
• Soldevilla MM, Villanueva H, Meraviglia-Crivelli D, et al. ICOS costimulation at the tumor site in combination with CTLA-4 blockade therapy elicits strong tumor immunity. Mol Ther. 2019;27(11):1878–1891. doi:10.1016/j.ymthe.2019.07.013
   PubMed Web of Science ®Google Scholar
• Losurdo A, Scirgolea C, Alvisi G, et al. Single-cell profiling defines the prognostic benefit of CD39 tissue resident memory CD8+ T cells in luminal-like breast cancer. Commun Biol. 2021;4:1117. doi:10.1038/s42003-021-02595-z
   PubMed Web of Science ®Google Scholar
• Fernando C, Behnaz B, Shroff Rachna T, et al. The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology. 2021;75:297–308.
   PubMed Web of Science ®Google Scholar
• Sarker MMK, Makhlouf Y, Craig Stephanie G, et al. A means of assessing deep learning-based detection of ICOS protein expression in colon cancer. Cancers. 2021;13. doi:10.3390/cancers13153825
   Web of Science ®Google Scholar
• Li C, Liu T, Liu Y, et al. Prognostic value of tumour microenvironment-related genes by TCGA database in rectal cancer. J Cell Mol Med. 2021;25:5811–5822. doi:10.1111/jcmm.16547
   PubMed Web of Science ®Google Scholar
• Metzger Todd C, Hua L, Potluri S, et al. ICOS promotes the function of CD4+ effector T cells during anti-OX40-mediated tumor rejection. Cancer Res. 2016;76:3684–3689. doi:10.1158/0008-5472.CAN-15-3412
   PubMed Web of Science ®Google Scholar
• Shi LZ, Goswami S, Fu T, et al. Blockade of CTLA-4 and PD-1 enhances adoptive T-cell therapy efficacy in an ICOS-mediated manner. Cancer Immunol Res. 2019;7:1803–1812. doi:10.1158/2326-6066.CIR-18-0873
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9:166–180. doi:10.1593/neo.07112
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77:e108–e110. doi:10.1158/0008-5472.can-17-0307
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8:740–801. doi:10.6004/jnccn.2010.0056
   PubMed Web of Science ®Google Scholar
• Wu CF, Fu JY, Yeh CJ, et al. Recurrence risk factors analysis for stage I non-small cell lung cancer. Medicine. 2015;94:e1337. doi:10.1097/MD.0000000000001337
   PubMed Web of Science ®Google Scholar
• He M, Wang Y, Shi WJ, et al. Immunomodulation of inducible co-stimulator (ICOS) in human cytokine-induced killer cells against cholangiocarcinoma through ICOS/ICOS ligand interaction. J Dig Dis. 2011;12:393–400. doi:10.1111/j.1751-2980.2011.00527.x
   PubMed Web of Science ®Google Scholar
• Amatore F, Gorvel L, Olive D. Inducible co-stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy. Expert Opin Ther Targets. 2018;22:343–351. doi:10.1080/14728222.2018.1444753
   PubMed Web of Science ®Google Scholar
• Burmeister Y, Lischke T, Dahler AC, et al. ICOS controls the pool size of effector-memory and regulatory T cells. J Immunol. 2008;180:774–782. doi:10.4049/jimmunol.180.2.774
   PubMed Web of Science ®Google Scholar
• Wikenheiser DJ, Stumhofer JS. ICOS co-stimulation: friend or foe? Front Immunol. 2016;7:304
   PubMed Web of Science ®Google Scholar
• leconte J, Bagherzadeh Yazdchi S, Panneton V, Suh WK. Inducible costimulator (ICOS) potentiates TCR-induced calcium flux by augmenting PLCγ1 activation and actin remodeling. Mol Immunol. 2016;79:38–46. doi:10.1016/j.molimm.2016.09.022
   PubMed Web of Science ®Google Scholar
• Yoshinaga SK, Zhang M, Pistillo J, et al. Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS. Int Immunol. 2000;12:1439–1447. doi:10.1093/intimm/12.10.1439
   PubMed Web of Science ®Google Scholar
• Kopf M, Coyle AJ, Schmitz N, et al. Inducible costimulator protein (ICOS) controls T helper cell subset polarization after virus and parasite infection. J Exp Med. 2000;192:53–61. doi:10.1084/jem.192.1.53
   PubMed Web of Science ®Google Scholar
• Akbari O, Freeman GJ, Meyer EH, et al. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med. 2002;8:1024–1032. doi:10.1038/nm745
   PubMed Web of Science ®Google Scholar
• Faget J, Bendriss-Vermare N, Gobert M, et al. ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. Cancer Res. 2012;72:6130–6141. PMID:23026134. doi:10.1158/0008-5472.CAN-12-2409
   PubMed Web of Science ®Google Scholar
• Faget J, Sisirak V, Blay JY, Caux C, Bendriss-Vermare N, Menetrier-Caux C. ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4 T cells by plasmacytoid dendritic cells. Oncoimmunology. 2013;2:e23185. doi:10.4161/onci.23185
   PubMed Web of Science ®Google Scholar
• Carthon Bradley C, Wolchok Jedd D, Yuan J, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010;16:2861–2871. doi:10.1158/1078-0432.CCR-10-0569
   PubMed Web of Science ®Google Scholar
• Shi LZ, Fu T, Guan B, et al. Interdependent IL-7 and IFN-gamma signalling in T-cell controls tumour eradication by combined alpha-CTLA-4+alpha-PD-1 therapy. Nat Commun. 2016;7:12335. doi:10.1038/ncomms12335
   PubMed Web of Science ®Google Scholar
• Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. PNAS. 2010;107:4275–4280. doi:10.1073/pnas.0915174107
   PubMed Web of Science ®Google Scholar
• Sainson Richard CA, Thotakura Anil K, Kosmac M, et al. An antibody targeting ICOS increases intratumoral cytotoxic to regulatory T-cell ratio and induces tumor regression. Cancer Immunol Res. 2020;8:1568–1582. doi:10.1158/2326-6066.CIR-20-0034
   PubMed Web of Science ®Google Scholar